Goldman Sachs’s Icosavax, Inc. Common Stock ICVX Stock Holding History

Goldman Sachs’s Portfolio ICVX Stock Details ICVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-295,984	Closed	-$4.66M	–	6002
2023 Q4	$4.66M	Buy	295,984 +267,148	+926%	+$2.57M	﹤0.01%	3218
2023 Q3	$223K	Sell	28,836 -36,177	-56%	-$300K	﹤0.01%	5002
2023 Q2	$646K	Sell	65,013 -290	-0.4%	-$2.32K	﹤0.01%	4601
2023 Q1	$379K	Buy	65,303 +53,354	+447%	+$461K	﹤0.01%	4986
2022 Q4	$94.9K	Sell	11,949 -27,607	-70%	-$118K	﹤0.01%	5491
2022 Q3	$125K	Sell	39,556 -29,709	-43%	-$186K	﹤0.01%	5628
2022 Q2	$397K	Buy	69,265 +50,937	+278%	+$397K	﹤0.01%	5243
2022 Q1	$129K	Sell	18,328 -2,390	-12%	-$37.6K	﹤0.01%	6023
2021 Q4	$474K	Buy	+20,718	New	+$535K	﹤0.01%	5427

Goldman Sachs's ICVX Position: Q1 2024 in Review

Goldman Sachs sold out of Icosavax, Inc. Common Stock (ICVX) in Q1 2024, closing a stake of 295,984 shares — an estimated $4.66M sold.

Goldman Sachs first reported a position in ICVX in Q4 2021 and held it in 9 quarters. The position peaked at $4.66M in Q4 2023. 0 funds tracked by Wall St. Rank hold ICVX as of Q1 2024.

Goldman Sachs reported no remaining Icosavax, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Goldman Sachs sold 295,984 Icosavax, Inc. Common Stock shares in Q1 2024, an estimated $4.66M.
Goldman Sachs first reported a position in Icosavax, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Goldman Sachs's Icosavax, Inc. Common Stock position peaked at $4.66M in Q4 2023.
0 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.